Evaluation of Anhedonia and Emotional Eating in Individuals Using GLP-1 Receptor Agonists

NCT07803185 | Recruiting

• 1 other identifier: 2026/173
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective observational study evaluates the longitudinal changes in anhedonia levels and emotional eating behaviors among adult individuals initiating glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight loss. Participants are assessed at baseline (treatment initiation) and after a 6-month follow-up period using standardized psychometric instruments.

Conditions

Obesity; Emotional Eating; Anhedonia

Keywords

GLP-1 Receptor Agonist; Glucagon-Like Peptide-1; Appetite Regulation; Reward System; Weight Loss

Outcome Measures

Primary Outcomes (1)

• Change in Dimensional Anhedonia Rating Scale (DARS) Score

  The DARS is a 17-item self-report questionnaire assessing state anhedonia across four domains (hobbies, food/drink, social activities, and sensory experiences). Each item is scored on a 5-point Likert scale from 0 ("Not at all") to 4 ("Extremely"), yielding a total score between 0 and 68. Lower scores indicate more severe anhedonia.

  Baseline and 6 months

Secondary Outcomes (1)

• Change in Emotional Eating Scale (EES) Score

  Baseline and 6 months

Study Arms (1)

GLP-1 Receptor Agonist Group

Adult participants who have newly initiated GLP-1 receptor agonist treatment for weight reduction and are evaluated at baseline and at 6 months.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients attending the Erciyes University Faculty of Medicine Endocrinology and Metabolism Outpatient Clinic who are newly prescribed GLP-1 receptor agonists for weight management.

You may qualify if:

• Age 18 years or older
• Newly initiated on GLP-1 receptor agonist treatment for weight reduction
• Willingness to participate in evaluations at baseline and at the 6-month follow-up
• Ability to read and understand Turkish and possess the cognitive capacity to answer questionnaire items
• Voluntary provision of written informed consent

You may not qualify if:

• Use of GLP-1 receptor agonists for indications other than weight loss
• Cognitive, neurological, or severe psychiatric conditions preventing completion of self-report questionnaires
• Substantial missing, inconsistent, or unverifiable questionnaire data compromising analysis integrity
• Non-participation or dropout at the 6-month follow-up evaluation

Sponsors & Collaborators

• TC Erciyes University: lead

Study Sites (1)

Erciyes University Medical Faculty Hospitals, Department of Endocrinology and Metabolism

Kayseri, Melikgazi, 38000, Turkey (Türkiye)

RECRUITING

Related Publications (2)

• Yapici-Eser H, Appadurai V, Eren CY, Yazici D, Chen CY, Ongur D, Pizzagalli DA, Werge T, Hall MH. Association between GLP-1 receptor gene polymorphisms with reward learning, anhedonia and depression diagnosis. Acta Neuropsychiatr. 2020 Aug;32(4):218-225. doi: 10.1017/neu.2020.14. Epub 2020 Mar 26.

  PMID: 32213216 BACKGROUND

• Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. Am J Med. 2025 Jun;138(6):934-940. doi: 10.1016/j.amjmed.2025.01.021. Epub 2025 Jan 31.

  PMID: 39892489 BACKGROUND

MeSH Terms

Conditions

Obesity; Emotional Eating; Anhedonia; Weight Loss

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Feeding Behavior; Behavior; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Body Weight Changes

Central Study Contacts

Hasan Durmuş, MD, Assoc. Prof.

CONTACT

+90 544 370 6917; asandurmus@erciyes.edu.tr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 6 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor, MD

Study Record Dates

• First Submitted: August 31, 2026
• First Posted: September 3, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: September 3, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)